Suppr超能文献

用于神经退行性疾病中线粒体靶向的纳米技术方法

Nanotechnological Approaches for Mitochondrial Targeting in Neurodegenerative Diseases.

作者信息

Ergin Ahmet Doğan

机构信息

Department Pharmaceutical Technology, Trakya University, Edirne, Turkey.

出版信息

Curr Top Med Chem. 2025 Jul 28. doi: 10.2174/0115680266397447250723073446.

Abstract

OBJECTIVES

Mitochondria are dynamic organelles essential for energy metabolism and cellular homeostasis, playing critical roles in ATP production, calcium regulation, redox balance, and apoptosis. However, mitochondrial dysfunction is a central factor in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Parkinson's disease. Given the essential role of mitochondria in neuronal survival, targeted therapeutic strategies that restore mitochondrial function have gained significant attention. This review explores the latest advances in mitochondrial-targeted therapies and their potential applications in neurodegenerative diseases.

METHODS

A comprehensive literature review was conducted on mitochondrial-targeted therapeutic strategies, with a focus on nanotechnology-based drug delivery systems. The analysis includes various nanoparticle-based approaches, such as liposomes, DQAsomes, and polymeric nanoparticles, which have demonstrated high biocompatibility, controlled drug release, and enhanced mitochondrial targeting efficiency. Additionally, mitochondria-penetrating peptides and delocalized lipophilic cations (DLCs) are discussed for their role in improving drug localization within mitochondria and overcoming biological barriers, including the blood-brain barrier (BBB).

RESULTS

Recent research shows the potential of mitochondrial-targeted antioxidants, peptides, and biocompatible nanocarriers in arranging mitochondrial dysfunction and protecting neurons from oxidative damage. Various nanoparticle-based drug delivery systems have demonstrated the ability to selectively target mitochondria, improving drug bioavailability, therapeutic efficacy, and neuroprotective outcomes in neurodegenerative diseases.

CONCLUSION

Mitochondria-targeted therapies provide promising avenues for disease-modifying treatments aimed at preserving neuronal integrity and delaying disease progression. The unique properties of nanoparticles, such as their ability to enhance drug stability, facilitate controlled release, and achieve precise mitochondrial localization, make them valuable tools for neurodegenerative disease therapy. Future research should focus on optimizing delivery systems, validating clinical applicability, and exploring interdisciplinary approaches to accelerate translation into effective treatments.

摘要

目的

线粒体是能量代谢和细胞稳态所必需的动态细胞器,在三磷酸腺苷(ATP)生成、钙调节、氧化还原平衡及细胞凋亡中发挥关键作用。然而,线粒体功能障碍是包括阿尔茨海默病、肌萎缩侧索硬化症、亨廷顿舞蹈病和帕金森病在内的神经退行性疾病发病机制的核心因素。鉴于线粒体在神经元存活中的重要作用,恢复线粒体功能的靶向治疗策略受到了广泛关注。本综述探讨了线粒体靶向治疗的最新进展及其在神经退行性疾病中的潜在应用。

方法

对线粒体靶向治疗策略进行了全面的文献综述,重点关注基于纳米技术的药物递送系统。分析包括各种基于纳米颗粒的方法,如脂质体、双喹啉酸脂质体和聚合物纳米颗粒,这些方法已证明具有高生物相容性、可控药物释放和增强的线粒体靶向效率。此外,还讨论了线粒体穿透肽和离域亲脂性阳离子(DLCs)在改善药物在线粒体内的定位以及克服包括血脑屏障(BBB)在内的生物屏障方面的作用。

结果

最近的研究表明,线粒体靶向抗氧化剂、肽和生物相容性纳米载体在改善线粒体功能障碍和保护神经元免受氧化损伤方面具有潜力。各种基于纳米颗粒的药物递送系统已证明能够选择性地靶向线粒体,提高药物在神经退行性疾病中的生物利用度、治疗效果和神经保护作用。

结论

线粒体靶向治疗为旨在维持神经元完整性和延缓疾病进展的疾病修饰治疗提供了有前景的途径。纳米颗粒的独特性质,如增强药物稳定性、促进可控释放和实现精确的线粒体定位的能力,使其成为神经退行性疾病治疗的有价值工具。未来的研究应集中在优化递送系统、验证临床适用性以及探索跨学科方法,以加速转化为有效的治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验